Sentences with phrase «recent efficacy trial»

A recent efficacy trial found that those randomized to MBRP, as compared with those in a control group, demonstrated significantly lower rates of substance use and greater decreases in craving following treatment.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

In recent years, medical researchers have proven its efficacy in clinical trials.

Although gene therapy research has made great strides in recent years, it has yet to be widely deployed, and no CRISPR - edited genes have yet been tested for safety or efficacy in human clinical trials.

Boni E. Elewski, M.D., professor of dermatology, is the principal investigator of the Efficacy of Response And Safety of two fixed secUkinumab REgimens in psoriasis (ERASURE) trial, one of two studies in the recent New England Journal of Medicine article «Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials.»

Vaccine efficacy was set at an average of 60 % (actual numbers depended on the different virus subtypes and on whether a person had been exposed due to a prior natural infection) based on recent phase III trial results for the Sanofi - Pasteur vaccine that had shown moderate effectiveness.

Results from recent clinical trials and studies in animals suggest that a class of anti-cancer drugs called angiogenesis inhibitors may be able to temporarily reduce interstitial pressure and improve the efficacy of chemotherapy and radiation treatments.

In a recent review of the distribution of research grant emphases in the area of violence, several NIH institutes classified their studies into one of three categories: (a) preintervention studies, which included risk or protective studies, population - based epidemiological studies, or basic prevention development; (b) efficacy studies, which included laboratory trials of the impact of specific preventive or treatment interventions targeted at disruptive behavior disorders, including conduct disorder; and (c) effectiveness research, which included studies of the effectiveness, dissemination, or transportability of interventions into community (nonacademic) settings.

The mean relapse rate is 50 % at one year and over 70 % at four years.1 A recent prospective twelve year follow - up study showed that individuals with bipolar disorder were symptomatic for 47 % of the time.2 This poor outcome in naturalistic settings suggests an efficacy effectiveness gap for mood stabilisers that has resulted in a re-assessment of the role of adjunctive psychological therapies in bipolar disorder.3 Recent randomised controlled trials show that the combination of pharmacotherapy and about 20 — 25 sessions of an evidence - based manualised therapy such as individual cognitive behaviour therapy4 or family focused therapy5 may reduce relapse rates in comparison to a control intervention (mainly treatment as usual) in currently euthymic people with bipolar disrecent prospective twelve year follow - up study showed that individuals with bipolar disorder were symptomatic for 47 % of the time.2 This poor outcome in naturalistic settings suggests an efficacy effectiveness gap for mood stabilisers that has resulted in a re-assessment of the role of adjunctive psychological therapies in bipolar disorder.3 Recent randomised controlled trials show that the combination of pharmacotherapy and about 20 — 25 sessions of an evidence - based manualised therapy such as individual cognitive behaviour therapy4 or family focused therapy5 may reduce relapse rates in comparison to a control intervention (mainly treatment as usual) in currently euthymic people with bipolar disRecent randomised controlled trials show that the combination of pharmacotherapy and about 20 — 25 sessions of an evidence - based manualised therapy such as individual cognitive behaviour therapy4 or family focused therapy5 may reduce relapse rates in comparison to a control intervention (mainly treatment as usual) in currently euthymic people with bipolar disorder.

She has been Primary Investigator or methodologist of 2 randomized controlled trials testing the efficacy of EFT for co-occurring depression and relationship discord, and of a recent NIMH funded study aimed to personalize treatment for depression.